More detailed knowledge of the synovial inflammation associated with IL17A+ and CD21L+ expression should highlight additional targets and might offer the future prospect of selecting biological therapy based on the definition of these different types of joint synovial inflammation. This evidence concerns the gene IL17A and inflammation.